Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Oct 25, 2020 4:23pm
104 Views
Post# 31778878

RE:RE:RE:RE:RE:RE:RE:RE:RE:Interesting Chart Pattern Shows.......

RE:RE:RE:RE:RE:RE:RE:RE:RE:Interesting Chart Pattern Shows.......WC,

You are doing the right thing, looking for the weakest link in this story, trying to really understand the company.

As per depth in the company, I would agree, they should look at succession planning sometime down the road as there is no one likely able to steer the ship besides Gilles.

As for resoucres, they did some restructuring earlier in the year and are getting help as needed. Additional resources include the addition of a PGX research scientst, the use of an agency to help negotiate deals, and help on a NASDAQ uplisting.  The latter 2 would be to alleviate the workload from Gilles.  I'm certain that as the company signs deals, they will beef up the operations and management team. 

WIth regards to financings and projects, they have enough working capital for now, Gilles has said that he would prioritize projects as needed.  Beyond the raise they did in 2016, they have done well enough with cash flow from their base business to support R&D. Perhaps after a deal is signed they may do a deal with an investment bank for sponsorship and become more shareholder friendly, likely taking advice from the investment banker on increasing the company's visibility on the street.




<< Previous
Bullboard Posts
Next >>